Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TER-2013 in Advanced Solid Tumors With AKT/PI3K/PTEN Pathway Alterations
NCT07109726Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of TER-2013 in solid tumor, breast cancer, endometrial cancer (EC), ovarian cancer, squamous cell carcinoma of the lung (LSCC). Started Sep 2025; status: recruiting.
02
Drugs
TER-2013
03
Conditions
solid tumorbreast cancerendometrial cancer (EC)ovarian cancersquamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT07109726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07109726.